Merck & Company, Inc. Press Releases

MRK 
$60.05
*  
0.17
0.28%
Get MRK Alerts
*Delayed - data as of Sep. 18, 2014 14:21 ET  -  Find a broker to begin trading MRK now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    MRK Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
9/17/2014 9:31:00 AM - Business Wire

Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab
9/17/2014 8:30:00 AM - Business Wire

Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis
9/15/2014 1:30:00 PM - Business Wire

Four New Partner Organizations Join Optum Labs Research Collaborative
9/9/2014 8:00:00 AM - Business Wire

Merck to Participate at the Morgan Stanley Global Healthcare Conference
9/8/2014 5:00:00 PM - Business Wire

Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy
9/4/2014 3:46:00 PM - PR Newswire

Merck’s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA
9/4/2014 9:00:00 AM - Business Wire

Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Company’s Investigational Anti-PD-1 Antibody, at ESMO 2014
9/2/2014 8:30:00 AM - Business Wire

Pfizer And Merck To Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen
8/26/2014 8:00:00 AM - Business Wire

Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal
8/15/2014 9:00:00 AM - PR Newswire

Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals
8/14/2014 9:00:00 AM - PR Newswire

Merck Statement regarding Role of PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumococcal Vaccination in Adults
8/13/2014 5:58:00 PM - Business Wire

FDA Approves BELSOMRA® (suvorexant) for the Treatment of Insomnia
8/13/2014 4:49:00 PM - Business Wire

Boston Millennia Partners Liquidity Events Realize More Than $100 Million of Value for its Limited Partners
8/6/2014 3:13:00 PM - Business Wire

Merck Publishes 2013 Global Corporate Responsibility Report
8/5/2014 1:00:00 PM - Business Wire

Merck Completes Tender Offer to Acquire Idenix
8/5/2014 6:00:00 AM - Business Wire

Merck Announces Second-Quarter 2014 Financial Results
7/29/2014 6:56:00 AM - Business Wire

Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients
7/24/2014 8:30:00 AM - Business Wire

Merck Announces Fourth-Quarter 2014 Dividend
7/23/2014 12:15:00 PM - Business Wire

Merck's HIV Campaign, I Design, Partners with Music Industry Promoter and HIV Advocate Maria Davis and Positive Women's Network - USA to Encourage Women Living with HIV to be "Vocal" about their Treatment
7/17/2014 8:30:00 AM - PR Newswire

Merck Announces Data from Investigational Phase 3 Study on EMEND® (aprepitant) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Undergoing Emetogenic Chemotherapy
6/30/2014 8:00:00 AM - Business Wire

MSD’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma
6/30/2014 6:00:00 AM - Business Wire

Merck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma
6/30/2014 6:00:00 AM - Business Wire

Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals
6/26/2014 8:00:00 AM - PR Newswire

Merck to Hold Second-Quarter 2014 Sales and Earnings Conference Call on July 29
6/23/2014 5:00:00 PM - Business Wire